A wholly novel approach to the treatment of refractory brain tumours
Glioblastoma multiforme (GBM) is the most common high-grade malignant brain tumour in adults. It is a devastating disease with a very poor 5-year survival rate of 5%, a figure which has not improved over the last few decades. The Targeted Therapy Group at the University of Surrey in collaboration with HOX Therapeutics and the Universities […]
A wholly novel approach to the treatment of refractory brain tumours Read More »